Novartis AG
FXR AGONISTS FOR THE TREATMENT OF LIVER DISEASES

Abstract:

The invention provides methods for treating or preventing a condition mediated by the farnesoid X receptor (FXR), comprising administering tropifexor, a pharmaceutically acceptable salt, an amino acid conjugate or an acyl glucuronide conjugate thereof, at a dose of about 140 .mu.g to about 250 .mu.g, to a subject in need thereof.